Factor Xa Fusion Constructs for High-Yield Active Protein Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing recombinant factor Xa and its derivatives face challenges in efficient expression and manufacturing due to the inability of host cell lines to process activation peptides, leading to reduced protein yield and functional activity.
Innovation Solution
The inclusion of an activation peptide fused to the C-terminal end of the heavy chain, combined with specific protease recognition sites and human serum albumin fusion, enhances protein expression and activity by producing a two-chain polypeptide capable of binding to factor Xa inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the activation peptide is removed to convert inactive fX to active fXa, then the protein becomes functionally active, but the host cell line cannot process and remove the activation peptide, leading to reduced protein yield
Solution Approach 1:
A fusion partner protein is introduced as an intermediary that enables the host cell to process the activation peptide through a surrogate mechanism, allowing both high-yield expression and functional activation of factor Xa
Solution Approach 2:
The activation peptide processing function is segmented from the host cell's native capability and assigned to a specialized fusion partner protein, which handles this specific task while allowing the main factor Xa production to proceed efficiently
2Productivity
If the activation peptide is retained to maintain expression efficiency, then protein yield increases, but the protein remains inactive and cannot bind to factor Xa inhibitors effectively
Solution Approach 1:
The fusion partner protein performs preliminary processing of the activation peptide during expression, enabling the factor Xa to be secreted in its active form while maintaining high expression levels through the fusion construct
Solution Approach 2:
The fusion partner protein provides self-service by autonomously processing the activation peptide of the fused factor Xa, eliminating the need for external proteases or additional processing steps
3Ease of manufacture
If conventional production methods are used without fusion partners, then the manufacturing process is simpler, but the ability to process activation peptides is lost, reducing overall production efficiency
Solution Approach 1:
The fusion partner protein serves multiple functions simultaneously: it acts as a secretion signal, enables activation peptide processing, and facilitates high-yield expression, all within a single protein construct that simplifies the overall manufacturing approach
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly improves the expression and functional activity of factor Xa proteins and derivatives, enabling efficient production and effective binding to factor Xa inhibitors, overcoming conventional limitations in manufacturing processes.
Implementation Method 1
L1 is a peptide linker comprising a protease recognition site
Implementation Method 2
two chains linked by a disulfide bond between the two chains
Implementation Method 3
binds to the inhibitor and relives its inhibition of fXa, thus restores normal coagulation activity of fXa
Data Source
AI summary
The present disclosure relates to protein sequences which can be used to generate factor Xa proteins and derivatives thereof. The protein sequences include a factor Xa light chain portion, a heavy chain catalytic domain portion, and an activation peptide C-terminal to the heavy chain catalytic domain portion.